Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.60+0.00 (+0.63%)

Close on Nov 12, 2026Market cap $165.40MP/E –Yield –

Humacyte price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Humacyte's price to sales ratio was 77.5× on Nov 11, 2026, against 136.5× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	77.5×	−19.6
2025	Dec 31, 2025	97.1×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HUMA.

Revenue growth52.5% · median -1.9%

Gross margin-475.1% · median 34.1%

Operating margin-4602.9% · median -1342.3%

Net margin-3955.1% · median -1156.2%

Advertisement
300 × 250

See a number that looks wrong?